MedPath

Chitosan Unguent in burned patients

Phase 2
Conditions
Superficial first and second degree burns
Burns
Wounds and Injuries
Registration Number
RPCEC00000256
Lead Sponsor
Center for Pharmaceutical Research and Development, Havana, Cuba.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
40
Inclusion Criteria

1- Cuban patients, of any sex, any skin color, with superficial burns, grades I and II.
2- Ages between 18 and 70 years, both inclusive.
3 - Burns by physical agents.
4- Written informed consent of the patient to participate in the investigation and to complete the established examinations.

Exclusion Criteria

1- Burns from electrical or chemical origin, by inhalation or combined.
2 - Presence of microbiologically confirmed sepsis in the lesions, caused by Pseudomonas aeruginosa or other bacterial agents.
3- History of allergy or hypersensitivity to any component of the formulation.
4- Diabetes mellitus.
5- Referred immunological disease.
6- Malignant disease.
7- Collagen disease.
8- Pregnancy, breastfeeding or puerperium.
9- Severe psychiatric disorder or mental incapacity.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Time of lesions healing (Time from baseline assessment until the moment of total healing of the lesions or the moment of formation of useful granulation tissue in the affected area). Measurement time: daily during the duration of the treatment.
Secondary Outcome Measures
NameTimeMethod
1. Extension of lesions (It will calculate using a simple method named Kirschbaum Rule or rule of 3, which constitutes a modification of the Wallace Rule (or rule of 9), by which it is considered that Different bodily anatomical regions represent 9% each or a multiple of 9% of total body surface area). Measurement time: at baseline and, then at days 7 and 14 of treatment or until the time of healing of the lesions.<br>2. Presence of local adverse events-AE (distribution frequency for the appearance of AE (Yes, No), type of event (name of the AE), duration (time from appearance until stop the event), severity (severe, non-severe), intensity of AE (grades 1-5), relation of causality (remote, possible, probable, very probable), result of AE (recuperate, improvement, persist or sequels), attitude concerning the studied treatment (without changes, dose modification, temporal or definitive treatment discontinuation)). Measuring time: At each administration until the end of treatment.<br>
© Copyright 2025. All Rights Reserved by MedPath